Skip to main content

We have the honor and pleasure of welcoming a new member to our Board of Directors – Mr. Thomas Kim.

Currently at the helm of EpiVario as President & CEO, Mr. Kim brings to the table a wealth of expertise in biotechnology, business leadership, and corporate law. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.

Prior to EpiVario, he served as Senior Vice President and Corporate Secretary for the public biopharmaceutical company, Inovio Pharmaceuticals, where he built a global biotechnology patent portfolio, led the company through various M&A transactions, and closed several licenses and partnering deals with large pharmaceutical companies. Mr. Kim has counseled and managed several early-stage biotechnology companies and has experience counseling biotechnology companies for over 23 years. He has practiced law at both large law firms and at Fortune 100 companies including Monsanto and DuPont. Mr. Kim has a Juris Doctor degree from Washington University in St. Louis, a Master of Science in biochemistry degree from the University of Illinois, Urbana, and a Bachelor of Science in chemistry degree from the Georgia Institute of Technology. In addition, he also serves as a member of Georgia Tech College of Science’s External Advisory Board.

The addition of Mr. Kim to the TANGO2 Research Foundation’s Board of Directors comes at a crucial juncture in our mission to drive research and find solutions for those impacted by TANGO2. His insights, experiences, and leadership will undeniably propel our endeavors forward.

Together, with his leadership and our collective passion, we are set to take the TANGO2 Research Foundation to greater heights.